Buprenorphine Hydrochloride

COMMACK, NY, May 18, 2026 (GLOBE NEWSWIRE) -- SCIENTURE HOLDINGS, INC. (NASDAQ: SCNX) (“Scienture”), a holding company for existing and planned pharmaceutical operating companies focused on providing enhanced value to patients, physicians and caregivers through the development, commercialization, and distribution of novel specialty products that address unmet market needs, today provided a business update and reported financial results for the three months ended March 31, 2026. Q1 2026 Financial Highlights Compared to Q1 2025: Revenue increased to approximately $56 thousand for the three months ended March 31, 2026, compared to approximately $10 thousand in the prior-year three-month period, representing an increase of approximately 449% year-over-year, reflecting incremental product orders for Arbli TM in addition to the initial launch quantities ordered in the fourth quarter of 2025 Gross profit increased substantially to approximately $54 thousand, compared to approximately $673 in the prior-year three-month period, representing an increase of approximately 7900% year-over-year, primarily as a result of the increase in Arbli TM product orders Gross margin expanded to approximately 95.6% for the three months ended March 31, 2026, compared to approximately 6.6% in the prior-year three-month period, also as a result of the increase in Arbli TM product orders Key Operational Highlights in Q1 2026 and Subsequent Events: United States Patent and Trademark Office (USPTO) granted a third patent covering Arbli TM (losartan potassium) oral suspension, further strengthening the product’s intellectual property portfolio and extending expected market exclusivity through 2041 Received an Orange Book-listable patent for REZENOPY TM (naloxone HCl) nasal spray 10 mg, the highest-dose FDA-approved naloxone HCl nasal spray for emergency opioid overdose treatment Formalized multiple commercial GPO agreements for REZENOPY TM , expanding access to over 5,000 healthcare institutions and reaching approximately 60% of the U.S. institutional market, including first responders, EMS providers, and rehabilitation centers Secured $11.0 Million in non-dilutive debt financing to accelerate growth of approved product portfolio and advancement of R&D pipeline Narasimhan Mani, President and Co-CEO of Scienture, commented, “Our financial results for the quarter reflect the early progress of our commercialization strategy, with revenue increasing approximately 449% year-over-year to $56 thousand, gross profit increasing approximately 7900% year-over-year to $54 thousand, and gross margin expanding significantly to approximately 95.6%, compared to 6.6% in the prior-year period. The increase in revenue and gross margin reflects incremental product orders received for Arbli TM during the first quarter of 2026, following the significant initial launch quantity orders recorded in the fourth quarter of 2025.” “During the quarter, we experienced continued month-over-month growth in both prescriptions and units sold for Arbli TM . We are actively working to enhance our promotional and commercial activities around the product to further increase physician awareness and market penetration. We also continue to advance key commercial initiatives to support the planned launch of REZENOPY TM . Our sales force is scheduled to begin operations on June 1, 2026, targeting key accounts and purchasing organizations, and we have also successfully secured key GPO contracts that we believe will support broad commercial access and accelerate adoption following launch. Together, we believe the continued commercialization of Arbli TM and the anticipated launch of REZENOPY TM will have a meaningful impact on our business performance during the second half of 2026,” added Mani. “In addition, we recently secured $11.0 million through a non-dilutive debt financing transaction that we believe significantly strengthens our capital position and provides important financial flexibility as we continue scaling our commercial operations,” stated Shankar Hariharan, Executive Chairman and co-CEO of Scienture. “We believe this financing will serve as a catalyst to help position the Company toward anticipated profitability in 2027, while also supporting the continued growth of our commercial product portfolio and the progression of our R&D pipeline.” Q1 2026 Financial Summary Revenue for the year three months ended March 31, 2026 increased 449% to $56 thousand, compared to $10 thousand in the prior year period, driven by the continued ramp of wholesale distribution sales of SCN-102 (Arbli TM ) following its commercial launch. Gross profit increased to approximately $54 thousand, compared to approximately $673 in the prior-year period, representing year-over-year growth of approximately 7900%. Total operating expenses remained relatively consistent at approximately $3.56 million for the period ended March 31, 2026, compared to approximately $3.57 million in the prior-year period, representing a slight decrease of approximately 0.2% year-over-year. Net loss was approximately $3.4 million for the period ended March 31, 2026, compared to approximately $3.1 million in the prior-year period. About Arbli TM Arbli TM is a novel proprietary formulation of losartan, a widely prescribed angiotensin receptor blocker (ARB) for hypertension. It is the first and only liquid formulation of losartan on the market that does not require compounding and has reduced dosing volume and long-term shelf life at room temperature storage. Arbli TM is FDA-approved for the treatment of hypertension in patients greater than six years old, for reducing the risk of stroke in patients with hypertension and left ventricular hypertrophy, and for treating diabetic nephropathy in certain patients with type 2 diabetes. By offering a safe, effective, and convenient liquid alternative, Arbli TM provides a tailored solution for patients who require or prefer a liquid formulation. As an FDA-approved product, Arbli TM provides consistent quality and dosing accuracy, addressing the risks and inconsistencies often associated with extemporaneously compounded losartan prescriptions. Arbli TM has two issued patents from the USPTO, which are also listed in the FDA Orangebook. Arbli TM is the first and only oral liquid formulation of losartan approved by the U.S. FDA. Arbli TM comes in a 165 mL bottle as a peppermint flavored suspension that does not require refrigeration and has been approved for a shelf life of 24 months from the date of manufacture when stored at room temperature. INDICATION Arbli TM is an angiotensin II receptor blocker (ARB) indicated for: Treatment of hypertension, to lower blood pressure in adults and children greater than 6 years old. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. Reduction of the risk of stroke in patients with hypertension and left ventricular hypertrophy. Treatment of diabetic nephropathy with an elevated serum creatinine and proteinuria in patients with type 2 diabetes and a history of hypertension. IMPORTANT SAFETY INFORMATION Do not take Arbli TM when pregnant. When pregnancy is detected, discontinue Arbli TM as soon as possible. Drugs that act directly on the renin-angiotensin system can cause injury and death to the developing fetus. Arbli TM can cause fetal harm when administered to a pregnant woman. Use of drugs that act on the renin-angiotensin system during the second and third trimesters of pregnancy reduces fetal renal function and increases fetal and neonatal morbidity and death. Do not co-administer Arbli TM with aliskiren in patients with diabetes. Avoid use of aliskiren with Arbli TM in patients with renal impairment (GFR <60 mL/min). Do not administer Arbli TM in patients with severe hepatic impairment. Arbli TM has not been studied in patients with severe hepatic impairment. The most common adverse reactions are (incidence ≥2% and greater than placebo): dizziness, upper respiratory infection, nasal congestion, and back pain. You are encouraged to report negative side effects of prescription drugs to the FDA. Visit , or call 1-800-FDA-1088. You may also contact Scienture at 1-833-754-4917. Please see the full Prescribing Information for complete product information. For more information, talk to your healthcare provider. About Hypertension Hypertension (high blood pressure) is a cardiovascular condition, when the pressure in the blood vessels is too high (140/90 mmHg or higher). According to the CDC, hypertension, or high blood pressure, affects nearly half of adults in the United States, or approximately 119.9 million people. Hypertension is defined as a systolic blood pressure of 140 mmHg or higher, and diastolic blood pressure of 90 mmHg or higher. Hypertension is a risk factor for stroke and heart disease, which are leading causes of death in the U.S. Factors that increase the risk of having high blood pressure include: older age, genetics, being overweight or obese, not being physically active, high-salt diet and drinking too much alcohol. Hypertension is clinically diagnosed if, when blood pressure is measured on two different days, the systolic blood pressure readings on both days is ≥140 mmHg and/or the diastolic blood pressure readings on both days is ≥ 90 mmHg. About REZENOPY TM REZENOPY TM (naloxone HCl) Nasal Spray 10mg, is an opioid antagonist indicated for the emergency treatment of known or suspected opioid overdose, as manifested by respiratory and/or central nervous system depression in adult and pediatric patients. It is intended for immediate administration as emergency therapy in settings where opioids may be present. REZENOPY TM nasal spray is for intranasal use only and is supplied as a carton containing two (2) blister packages each with a single spray device. IMPORTANT SAFETY INFORMATION REZENOPY TM (naloxone hydrochloride) Nasal Spray 10 mg is an opioid antagonist indicated for the emergency treatment of known or suspected opioid overdose, as manifested by respiratory and/or central nervous system depression in adult and pediatric patients. It is intended for immediate administration as emergency therapy in settings where opioids may be present and is not a substitute for emergency medical care. Important Safety Information Contraindications: REZENOPY TM nasal spray is contraindicated in patients known to be hypersensitive to naloxone hydrochloride or to any of the other ingredients. Warnings and Precautions: Risk of Recurrent Respiratory and CNS Depression: Due to the duration of action of naloxone relative to the opioid, keep the patient under continued surveillance and administer additional doses as necessary while awaiting emergency medical assistance. Risk of Limited Efficacy with Partial Agonists or Mixed Agonists/Antagonists: Reversal of respiratory depression caused by partial agonists or mixed agonists/antagonists, such as buprenorphine and pentazocine, may be incomplete. Larger or repeat doses may be required. Precipitation of Severe Opioid Withdrawal: Use in patients who are opioid-dependent may precipitate opioid withdrawal. In neonates, opioid withdrawal may be life-threatening if not recognized and properly treated. Monitor for the development of opioid withdrawal. Risk of Cardiovascular Effects: Abrupt postoperative reversal of opioid depression may result in adverse cardiovascular effects. These events have primarily occurred in patients who had pre-existing cardiovascular disorders or received other drugs that may have similar adverse cardiovascular effects. Monitor these patients closely in an appropriate healthcare setting after use of naloxone hydrochloride. Adverse Reactions: The following adverse reactions were observed in a REZENOPY TM nasal spray clinical study: upper abdominal pain, nasopharyngitis, and dysgeusia. For complete product information, including Patient Information, please refer to the full Prescribing Information. About Scienture Holdings, Inc. SCIENTURE HOLDINGS, INC. (NASDAQ: SCNX), through its wholly owned subsidiary, Scienture, LLC, is a comprehensive pharmaceutical product company focused on providing enhanced value to patients, physicians and caregivers by offering novel specialty products to satisfy unmet market needs. Scienture, LLC is a branded, specialty pharmaceutical company consisting of a highly experienced team of industry professionals who are passionate about developing and bringing to market unique specialty products that provide enhanced value to patients and healthcare systems. The assets in development at Scienture are across therapeutics areas, indications and cater to different market segments and channels. For more information please visit: and . Cautionary Statements Regarding Forward-Looking Statements This press release contains certain statements that may be deemed to be “forward-looking statements” within the federal securities laws, including the safe harbor provisions under the Private Securities Litigation Reform Act of 1995. Statements that are not historical are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements relate to future events or our future performance or future financial condition. These forward-looking statements are not historical facts, but rather are based on current expectations, estimates and projections about our company, our industry, our beliefs and our assumptions. Such forward-looking statements include, but are not limited to, statements regarding our or our management team’s expectations, hopes, beliefs, intentions or strategies regarding the future, including for the products we may launch, the success those products may have in the marketplace, such as Arbli TM and REZENOPY TM , and our strategies related to those products. In addition, any statements that refer to projections, forecasts or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking statements. In some cases, you can identify forward-looking statements by the following words: “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “ongoing,” “plan,” “potential,” “predict,” “project,” “should,” or the negative of these terms or other similar expressions, but the absence of these words does not mean that a statement is not forward-looking. Forward-looking statements are subject to a number of risks and uncertainties (some of which are beyond our control) that may cause actual results or performance to be materially different from those expressed or implied by such forward-looking statements. Accordingly, readers should not place undue reliance on any forward-looking statements. These risks include risks relating to agreements with third parties; our ability to raise funding in the future, as needed, and the terms of such funding, including potential dilution caused thereby; our ability to continue as a going concern; security interests under certain of our credit arrangements; our ability to maintain the listing of our common stock on the Nasdaq Stock Market LLC; claims relating to alleged violations of intellectual property rights of others; the outcome of any current legal proceedings or future legal proceedings that may be instituted against us; unanticipated difficulties or expenditures relating to our business plan; and those risks detailed in our most recent Annual Report on Form 10-K, as amended, and subsequent reports filed with the Securities and Exchange Commission. Forward-looking statements speak only as of the date they are made. Scienture Holdings, Inc. undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise that occur after that date, except as otherwise provided by law. Contact : SCIENTURE HOLDINGS, INC. 20 Austin Blvd Commack, NY 11725 Phone: (866) 468-6535 Email: IR@Scienture.com Scienture Holdings, Inc. Condensed Consolidated Balance Sheets As of March 31, 2026 and December 31, 2025 (Unaudited) March 31, December 31, 2026 2025 ASSETS Current assets: Cash and cash equivalents $ 3,542,754 $ 6,662,008 Accounts receivable, net 722,545 731,328 Inventory 210,934 213,408 Prepaid expenses 250,427 262,278 Deferred offering costs 47,384 47,384 Total current assets 4,774,044 7,916,406 Property, plant and equipment, net 15,000 15,500 Notes receivable 5,000,000 5,000,000 Interest receivable 343,750 250,000 Intangible assets, net 70,519,218 70,973,064 Operating lease right-of-use assets 9,693 23,360 Total assets $ 80,661,705 $ 84,178,330 LIABILITIES AND STOCKHOLDERS’ EQUITY Current liabilities: Accounts payable $ 1,404,794 $ 1,443,266 Accrued liabilities 703,872 657,034 Operating lease liability - current 10,004 24,137 Warrant liability - 10,914 Development agreement liability - current portion 685,000 600,000 Total current liabilities 2,803,670 2,735,351 Development agreement liability - 285,000 Deferred tax liability 11,037,595 11,037,595 Total liabilities 13,841,265 14,057,946 Commitments and contingencies (Note 15) Stockholders’ equity: Series A preferred stock, $0.00001 par value; 0 and 9,211,246 shares authorized; 0 shares issued and outstanding as of both March 31, 2026 and December 31, 2025 - - Series B preferred stock, $0.00001 par value; 787,754 shares authorized; 15,759 shares issued and outstanding as of both March 31, 2026 and December 31, 2025 - - Series C preferred stock, $0.00001 par value; 1,000 shares authorized; 0 shares issued and outstanding as of both March 31, 2026 and December 31, 2025 - - Series X preferred stock, $0.00001 par value; 9,211,246 shares authorized; 0 shares issued and outstanding as of both March 31, 2026 and December 31, 2025 - - Common stock, $0.00001 par value; 100,000,000 shares authorized; 40,630,815 and 40,630,815 shares issued and outstanding as of March 31, 2026 and December 31, 2025, respectively 1,015,000 and 1,015,000 shares unvested as of March 31, 2026 and December 31, 2025, respectively 406 406 Additional paid-in capital 150,773,535 150,671,215 Accumulated deficit (83,953,501 ) (80,551,237 ) Total stockholders’ equity 66,820,440 70,120,384 Total liabilities and stockholders’ equity $ 80,661,705 $ 84,178,330 Scienture Holdings, Inc. Condensed Consolidated Statements of Operations For the Three Months Ended March 31, 2026 and 2025 (Unaudited) Three Months Ended March 31, 2026 2025 Revenues $ 56,325 $ 10,258 Cost of sales 2,475 9,585 Gross profit 53,850 673 Operating expenses: Wage and salary expense 420,008 696,068 Professional fees 932,552 412,850 Accounting and legal expense 326,178 470,825 Technology expense 15,763 61,620 General and administrative 1,074,864 1,355,948 Research and development 793,984 574,679 Total operating expenses 3,563,349 3,571,990 Operating loss (3,509,499 ) (3,571,317 ) Non-operating income (expense): Change in fair value of warrant liability 10,910 645,986 Change in fair value of derivative liability - 603,322 Loss on conversion of note payable - (96,646 ) Interest income 133,344 25,442 Interest expense (37,019 ) (670,784 ) Total non-operating expense 107,235 507,320 Benefit (provision) for income taxes - - Net loss $ (3,402,264 ) $ (3,063,997 ) Net loss per common share Basic $ (0.08 ) $ (0.33 ) Diluted $ (0.08 ) $ (0.33 ) Weighted average common shares outstanding Basic 40,630,815 9,425,751 Diluted 40,630,815 9,425,751

Key Regulatory Benchmark Met, Differentiating DMX-101 from Traditional Opioid Analgesics Late-Breaking Results to be Presented at CPDD 2026 Annual Meeting San Francisco, California--(News - May 12, 2026) - DIMERx, Inc. ("DIMERx" or "the Company") is a clinical-stage biopharmaceutical company dedicated to addressing the public-health crisis of drug misuse and dependence, with a portfolio of first-in-class, dimer-based pain therapeutics engineered to deliver effective analgesia without the addiction liabilities of conventional opioids. In June 2025, DIMERx was awarded a NIH HEAL Initiative grant to advance its DMX-101 program. The company today announced preclinical data confirming that DMX-101, an orally bioavailable, peripherally acting new chemical entity (NCE) dimer of buprenorphine, is free of the reinforcing effects that drive addiction to traditional opioids. In a self-administration study conducted in accordance with FDA guidance, cocaine- and hydrocodone-trained rats demonstrated that DMX-101 produced no reinforcing behavior characteristic of opioid misuse and dependence. All compounds were administered intravenously to maximize pharmacological exposure, representing a worst-case scenario for misuse potential assessment. Notably, DMX-101 plasma exposure levels in rats were 18-fold higher than the maximum plasma concentration (Cmax) observed in humans following oral dosing, indicating that the absence of rewarding effects was demonstrated at exposures substantially exceeding those expected in clinical use. Even under these rigorous conditions, DMX-101 showed no evidence of addictive behavior, supporting a favorable safety pro respect to misuse liability, overdose risk, and opioid-related morbidity. "DMX-101 is designed to exclusively target peripheral opioid receptors, blocking pain signals at their source without engaging central nervous system pathways linked to reward, sedation, or addiction, and the absence of self-administration behavior observed in this study supports the potential for DMX-101 to provide effective pain relief without the risk of misuse," said Virginia Sanders, PhD, Vice President of Preclinical and Principal Investigator for the NIH grant. "These results, together with prior preclinical and clinical findings, confirm our core hypothesis that peripherally restricted opioid modulation can deliver meaningful analgesia without the liabilities of traditional opioids. As the clinical and societal need for safer pain therapies intensifies, DMX-101 represents a differentiated approach to delivering meaningful analgesia without cognitive impairment or contributing to the addiction epidemic." "DMX-101 could redefine pain treatment. The absence of rewarding effects, even at exposures 18-fold above clinical levels, suggests we are looking at a genuinely differentiated therapy, one with the potential to displace traditional opioids and change the trajectory of the addiction crisis," said Eric C. Strain, MD, Professor of Psychiatry and Behavioral Sciences at Johns Hopkins University School of Medicine and an expert in addiction medicine and Scientific Advisor to DIMERx. DIMERx will present these findings at the College on Problems of Drug Dependence (CPDD) 88th Annual Meeting, June 13-17, in Portland, OR. Virginia Sanders, PhD and Eric C. Strain, MD, will present the data. Poster Details: Title: DMX-101 Does Not Exhibit Reinforcing Effects in a Hydrocodone-Trained Rat Self-Administration Model Session: Poster II Date/Time: Monday, June 15, 2026; 5:00pm-6:30pm Location: OCC, Level 1, Exhibit Hall A About DIMERx, Inc. DIMERx, Inc. is a clinical-stage biopharmaceutical company developing first-in-class, covalently linked dimer-based therapeutics to address major public-health challenges in pain management and the opioid crisis. Co-founded by CEO Nikhilesh Singh, M.Pharm, PhD, and CFO/COO Gregory Beyer, DIMERx is building a pipeline of innovative dimer-based candidates targeting pain and other serious conditions with high unmet medical need. The company's lead asset, DMX-101, is a covalently modified, chemically stable, halogen-free buprenorphine dimer (CAS No: 1820753-68-1) that acts peripherally at the source to provide non-addictive pain relief. DMX-101 is in phase 2 clinical development for chronic lower back pain. Across Phase 1 and Phase 2a studies involving over 400 subjects and patients, it has demonstrated a favorable safety profile, including pancreatic safety, and clear analgesic benefits. The DMX-101 program, which includes a planned human abuse liability study, is supported by a grant awarded by the National Institute on Drug Abuse (NIDA) under the NIH HEAL Initiative. DIMERx's second program, DMX-201, is a covalently linked dimer of arginine and agmatine, a next-generation nitric oxide (NO) donor being developed for conditions involving endothelial dysfunction, such as vaso-occlusive crisis (VOC) pain in sickle cell disease, where treatment options remain dominated by centrally acting opioids. Learn more at . Funding Disclosure and Forward-Looking Statements Research reported in this press release was supported by the National Institute on Drug Abuse of the National Institutes of Health under award number 1 UG3 DA061645-01A1. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. This press release may contain forward-looking statements, including information about management's view of DIMERx ("the Company"), future expectations, plans and prospects. In particular, when used in the preceding discussion, the words "believes," "expects," "intends," "plans," "anticipates," or "may," and similar conditional expressions are intended to identify forward-looking statements. Any statements made in this presentation other than those of historical fact, about an action, event or development, are forward-looking statements. These statements involve known and unknown risks, uncertainties and other factors, which may cause the results of the Company, its subsidiaries and concepts to be materially different than those expressed or implied in such statements. Unknown or unpredictable factors also could have material adverse effects on the Company's future results. The forward-looking statements included in this presentation are made only as of the date hereof. The Company cannot guarantee future results, levels of activity, performance or achievements. Accordingly, you should not place undue reliance on these forward-looking statements. Finally, the Company undertakes no obligation to update these statements after the date of this release, except as required by law, and also takes no obligation to update or correct information prepared by third parties that are not paid for by DIMERx. Investor Contact Hanover International Inc. Kathy Cusumano, President IR@dimerx.com To view the source version of this press release, please visit